1 The mechanism of cryoinjury was investigated in human internal mammary arteries (IMA) by monitoring contractile responses to ET-1 and KCl. 2 For cryopreservation segments of IMA were equilibrated for 20 min with the cryomedium (RPMI 1640 culture medium containing 1.8 M DMSO and 0.1 M sucrose), frozen at a mean cooling rate of 1.38C min 71 to 7708C and stored in liquid nitrogen. Before use, samples were thawed slowly and the cryomedium removed by dilution.
Introduction
Cryopreserved human blood vessels may become important tools in both bypass surgery and peripheral vascular reconstruction in patients without sucient autologous graft material (Brockbank, 1995; Fujitani et al., 1992) and are actually interesting topics of pharmacological research (MuÈ ller-Schweinitzer, 1994a, b; 1998; MuÈ ller-Schweinitzer & Fozard, 1997) . However, evidence has been presented that after thawing of cryostored human arteries the compliance of the blood vessel is diminished (MuÈ ller-Schweinitzer, 1994a, b) while at the same time the sensitivity of smooth muscle cells to contractile stimuli may be enhanced as indicated by a leftward shift of the concentration-response curves to various agonists in human coronary, mesenteric and internal mammary arteries (MuÈ ller-Schweinitzer et al., 1997; 1998) . Previous experiments on human internal mammary arteries have suggested that cryopreservation facilitates contractile responses induced by activation of protein kinase C (PKC) which seems to be associated with increased Ca 2+ in¯ux through dihydropyr-idine-sensitive Ca 2+ channels. Moreover, evidence has been presented that these changes were indeed related to freezing injury and not simply a consequence of exposure to the hypertonic cryomedium (MuÈ ller-Schweinitzer et al., 1998) .
Using two agonists with dierent mechanisms of action, namely endothelin-1 (ET-1) and potassium chloride (KCl), the present experiments extend these studies and add support to the contention that cryopreservation of human IMA activates PKC and enhances Ca 2+ in¯ux thereby modifying responses to contractile agonists in a dierent way.
Methods

Storage methods
Internal mammary arteries (10 ± 30 mm long, inner diameter *1 mm) were obtained during bypass surgery or excised from multiple organ donors after obtaining permission of the patient and approval from the local ethical committee. The preparations were placed in Krebs-Henseleit (KH) solution (composition mM): NaCl 118, KCl 4.7, MgSO 4 1.2, CaCl 2 1.25, KH 2 PO 4 1.2, NaHCO 3 25, glucose 11, EDTA 0.03, at room temperature and transported to the laboratory. The arteries were cleaned of loose connective tissue and used in organ bath studies either unfrozen or following cryostorage. For cryopreservation the arterial segments (10 ± 20 mm long) were suspended in 2 ml liquid nitrogen storage ampules (Life Technologies AG, Basel, Switzerland) ®lled with 1.6 ml RPMI 1640 culture medium containing 1.8 M DMSO and 0.1 M sucrose (MuÈ ler-Schweinitzer & Ellis, 1992) . After an equilibration time of 10 ± 20 min at room temperature the samples were placed into a polystyrene box (wall thickness & 10 mm) and slowly frozen in a freezer maintained at 7708C. Under these conditions the mean cooling rate is about 1.38C min 71 (MuÈ ller-Schweinitzer et al., 1998) . About 2 h later the ampules were transferred into liquid nitrogen and stored at 71968C. Before use the samples were ®rst placed for 10 min on dry ice before being exposed for 6 min to room temperature and thawed within 4 min in a 408C water bath at a mean thawing rate of about 158C min 71 (MuÈ ller-Schweinitzer et al., 1998) . Thereafter the preparations were placed for 10 min in KH solution containing 50% cryomedium before being transferred into a dish containing 10 ml KH solution at room temperature to remove the cryoprotecting agents.
Organ bath studies
After thawing, the arterial segments were cut into rings (about 2 mm long), mounted between two hooks of stainless steel wire (diameter 0.15 mm) and suspended in 10 ml organ baths containing KH solution at 378C, gassed continuously with 5% CO 2 in oxygen. Changes in the tone of the preparations were recorded isometrically under a resting tension of 1 g with electromechanical transducers (Statham model UC 3, Gould Inc., Oxnard, CA, U.S.A.) and a potentiometric recorder. At the beginning of the experiments the rings were stretched to an initial tension of about 1.5 g and allowed to relax and equilibrate for about 2 ± 3 h in the bathing medium. During this time the baseline tension of the rings was readjusted to 1 g if required and the vascular preparations were challenged once with noradrenaline (1 mM). When the noradrenaline eect was leveling o, the presence of functional endothelial cells was tested by adding 1 mM acetylcholine. Only arteries without signi®cant endothelial function were employed in the present study. When endothelin-1 (ET-1) was used as the agonist, the contractile force of each ring was ®rst determined by addition of 3 mM PGF 2a the eect of which was taken as point of comparison for subsequent responses to ET-1. Concentration-response curves for agonists were established by cumulative addition of drug, the concentration being increased when the maximum eect had been produced by the previous concentration. Responses were expressed in g or as percentages of the maximal eects of the control curves. Antagonists were added 20 min before the ®rst administration of the agonist. Experiments with nifedipine were performed in organ baths protected from light to avoid inactivation of the compound.
Drugs
The following drugs were used: (7)-noradrenaline hydrogen tartrate (Fluka, Buchs, Switzerland), acetylcholine chloride (Dispersa A.G., Hettlingen, Switzerland), endothelin-1 (ET-1, Novabiochem, LaÈ ufel®ngen, Switzerland), nifedipine, staurosporine (Sigma, Munich, Germany), prostaglandin F 2a (PGF 2a , Dinolytic, Upjohn, Crawley, U.K.). Nifedipine was dissolved in ethanol to give a 1 mM solution containing 60% ethanol and further diluted in distilled water. Staurosporine was dissolved in DMSO and diluted in distilled water to give a 0.1 mM solution containing 10% DMSO. Samples of 0.1 mM ET-1, 1 mM PGF 2a and 10 mM staurosporine were stored at 7208C. Before use, serial dilutions were performed with physiologic NaCl solution.
Data analysis
Computerized analysis of concentration-response curves was performed using the procedure Fit Function in RS/1 (BBN Software Products Corporation, Cambridge, MA, U.S.A.) according to the equation f(x)=A/(1+B/X) where f(x) is the fraction of receptors activated by the agonist concentration X, A represents the maximal response (E max ) and B represents the EC 50 values (concentration of the agonist producing 50% of E max ). Where appropriate, one-way analysis of variance (ANOVA) was performed, followed by the Bonferronicorrected t-test to assign dierences to individual betweengroup comparisons when overall signi®cance (P50.05) was attained. Data are presented as mean values+s.e.mean.
Results
Contractile responses to endothelin-1
Contractile responses to ET-1 of unfrozen and cryostored IMA are shown in Figure 1 . Cryopreservation of IMA did not diminish the maximal contractile responses to ET-1. After Figure 1 Contractile responses of human IMA (a) to cumulatively added ET-1 expressed in g on unfrozen (n=27) and cryostored IMA (n=45) and (b) to a single submaximal concentration of 100 nM ET-1 without and after cryostorage expressed in percentages of the corresponding normalized control eect (for each n=11). Vertical lines represent+s.e.mean. thawing of cryostored IMA ET-1 elicited maximal contraction of 1.96+0.19 g which was not signi®cantly dierent from that produced in unfrozen arteries (1.70+0.25 g). However, as indicated by the calculated apparent pD 2 values (8.70+0.04 vs 8.24+0.09), cryopreservation induced a signi®cant sensitization of the arterial smooth muscle, i.e., the contractile responses to ET-1 occurred at 3 fold lower concentrations (P50.001) than in unfrozen arteries ( Figure 1a , Table 1 ).
Contractile responses of unfrozen IMA to addition of a single submaximal concentration of ET-1 (100 nM) consisted of an initial phasic contraction which reached its maximum within 10 min followed by a slow decline to 25% after 90 min. In cryostored arteries the response to a single addition of ET-1 (100 nM) again consisted of an initial phasic contraction within 10 min which, however, remained relatively stable declining to 70% of the initial maximum after 90 min which was signi®cantly (P50.001) higher than that in unfrozen arteries (Figure 1b) .
To investigate the role of extracellular Ca 2+ , cumulative concentration-response curves to ET-1 were performed without and in the presence of nifedipine. The Ca 2+ entry blocker diminished in both unfrozen and cryostored IMA the maximal ET-1 eect in a concentration-dependent manner without changing the pD 2 values. However, in unfrozen human IMA responses to ET-1 were resistant to Ca 2+ channel blockade by up to 10 nM nifedipine. If used at 100 nM, nifedipine eliminated 40% of the maximal ET-1 eect, higher concentrations of nifedipine produced no further inhibition. In contrast, responses of cryostored IMA to ET-1, proved to be considerably more susceptible to Ca 2+ channel blockade by nifedipine. On the basis of the calculated IC 50 values nifedipine proved to be 5 fold more potent against ET-1 when tested in cryostored IMA (IC 50 =7 nM) than in unfrozen controls (IC 50 =35 nM, Figure 2) .
A further series of experiments was performed to study the role of protein kinase C (PKC) in the mechanism of action of ET-1. In these experiments contractile responses to ET-1 (100 nM) were determined without and in the presence of a high concentration of the PKC inhibitor staurosporine (100 nM). In unfrozen IMA blockade of the PKC activity by staurosporine did not modify the time course of a single contraction to ET-1. In contrast, it was found that after cryostorage treatment with staurosporine reversed the longlasting tonic contraction in response to a single addition of ET-1, i.e., in the presence of staurosporine the response to 100 nM ET-1 consisted of an initial phasic contraction followed by a progressive decline of the tone becoming superimposable to the curve obtained with unfrozen controls (Figure 3 ).
Contractile responses to depolarization by KCl
Exposure of unfrozen IMA to cumulatively increasing concentrations of KCl produced maximal contractions of 2.64+0.43 g. Following cryopreservation the maximal contractile response to depolarization was signi®cantly diminished to 1.09+0.11 g (P50.001). On the other hand, cryopreservation induced a considerable sensitization of the smooth muscle to stimulation by KCl, i.e., though less eective, KCl was 2 fold more potent (P50.001) in cryostored IMA than in unfrozen controls (Figure 4a , Table 1 ). However, in contrast to that observed with ET-1, in both unfrozen and cryostored IMA the time course of contraction to a single concentration of KCl (60 mM) consisted of a rapid increase in tone followed by a long-lasting stable contraction during the following 90 min of observation ( Figure 4b ).
Blockade of Ca 2+ channels by nifedipine (0.3 ± 100 nM) inhibited contractile responses to 60 mM KCl on both unfrozen and cryostored IMA in a concentration-dependent way and within fairly the same concentration range. In unfrozen IMA nifedipine eliminated up to 68% of the maximal KCl eect with an IC 50 of 2.6 nM. After cryostorage the blockade of KCl by nifedipine was slightly more eective approaching 90% of E max with an IC 50 of 1.3 nM ( Figure 5 ). In additional experiments the time course of a single concentration of KCl (60 mM) was recorded over 90 min without and during PKC inhibition by staurosporine (100 nM). It was found that in unfrozen IMA blockade of PKC diminished the KCl eect only slightly by 18%, whereas in cryostored IMA, the KCl-induced tone, after reaching a maximum within 20 min, declined progressively during the following time of observation eliminating 72% of the maximum after 90 min (Figure 6 ).
Discussion
The aim of the present experiments was to elucidate the nature of cryoinjury in human IMA using two contractile agonists with dierent mechanisms of action, namely endothelin-1 (ET-1) and potassium chloride (KCl). The contractile responses to both agents require increases in intracellular calcium which may be produced (1) by release of Ca 2+ into the cytoplasm from bound intracellular Ca 2+ stores and/or from extracellular sites triggered by membrane receptors, e.g., Ca 2+ in¯ux through receptor-operated Ca 2+ channels (ROC); or (2) in response to membrane depolarization and Ca 2+ in¯ux through voltage-operated Ca 2+ channels (VOC) (Yang et al., 1990; Godfraind et al., 1992; He et al., 1994; Pollock et al., 1995) . ET-1, a potent naturally occurring vascular smooth muscle contracting substance, was used as a receptor activating agent. KCl served as a membrane depolarizing agent to open dihydropyridine-sensitive VOC.
In human IMA contractile responses to ET-1 are mediated by both ET A and ET B receptor subtypes (Seo et al., 1994; Tschudi & LuÈ scher, 1994; Maguire & Davenport, 1995) . In those reports ET-1 has been shown to stimulate human IMA in vitro with EC 50 values of 3 ± 8 nM which correspond to the values determined in the present experiments. Upon stimulation of the ET-1 receptor a pertussis toxin-insensitive Gprotein is activated which stimulates phospholipase C (PLC). PLC then catalyses the breakdown of phosphoinositide 4,5bisphosphate to inositol 1,4,5-triphosphate (IP 3 ) and diacylglycerol (DAG) triggering the release of Ca 2+ from intracellular stores and activating PKC respectively (Pollock et al., 1995) . The release of Ca 2+ from intracellular stores is followed by Ca 2+ in¯ux from the extracellular space which accounts for the sustained contraction. The exact mechanism(s) by which this extracellular Ca 2+ enters the cell is not clearly de®ned. However, normally dihydropyridine-sensitive L-type Ca 2+ channels (VOC) seem to account for only a small if any portion in the ET-1 contraction of human IMA (Yang et al., 1990; He et al. 1994) . The resistance of ET-1 responses to Ca 2+ entry blockade by nifedipine in unfrozen IMA supports this contention. When tested after cryopreservation, however, nifedipine proved to be 5 fold more potent against ET-1 suggesting the involvement of dihydropyridine-sensitive Ca 2+ channels in the mechanism of action of ET-1. Against this background the enhanced susceptibility to Ca 2+ entry blockade of cryostored IMA strongly suggested that the freezing/thawing procedure had activated dihydropyridinesensitive Ca 2+ channels thereby promoting Ca 2+ -in¯ux into the smooth muscle cells. When in unfrozen IMA the activity of PKC was blocked by staurosporine no signi®cant reduction of the ET-1 contraction was obtained indicating that under normal conditions PKC contributes only little to the ET-1 eect. In contrast, when the PKC activity in frozen/thawed IMA was blocked the tonic contraction to ET-1 was reversed suggesting that the freezing/thawing procedure also enhanced the activity of PKC which then mediated the sustained ET-1 contraction in cryopreserved arteries. These observations suggested, therefore, that in cryostored IMA both enhanced Ca 2+ in¯ux and activated PKC contributed to and modi®ed the mechanism of action of ET-1.
When investigated in unfrozen isolated blood vessels KCl is one of the most eective contractile agents in vascular smooth muscle. The marked reduction after cryostorage of the contractile eectiveness of KCl to 40% of that produced by unfrozen IMA was, therefore, rather unexpected. This ®nding could be explained by enhanced basal Ca 2+ in¯ux as a consequence of cryoinjury produced by the freezing/thawing process and/or by the combined action of exposure of the vascular tissue to the hypertonic cryomedium and low temperature. If cryoinjury induces an elevation in the basal levels of cytosolic Ca 2+ , contractile responses to additional Ca 2+ in¯ux following depolarization must be attenuated. In the present study, nifedipine was only slightly more active in antagonizing K + -contractions in cryostored IMA than in unfrozen tissues. Furthermore, as observed with ET-1, blockade of PKC reversed the sustained KCl-induced tone in cryostored IMA considerably stronger than in unfrozen controls again suggesting that in addition to enhanced basal Ca 2+ in¯ux activation of PKC contributed to the K +contraction in cryostored IMA.
Taken together, the present experiments support the contention that the freezing/thawing process induced cellular responses which are characterized by transmembrane Ca 2+ in¯ux and activation of PKC. The data also suggest that the vasculature is receptive not only to pharmacologically active substances but also to physical forces such as cell shrinkage, mechanical stretch and transmural pressure which may occur during exposure to hypertonic solutions and low temperatures. Indeed, it has been shown that both high glucose concentration (Smogorzewski et al., 1998) and arterial contraction produced by quick stretch (Nakayama & Tanaka, 1993) are associated with an increase in intracellular Ca 2+ due to both Ca 2+ in¯ux through dihydropyridine-sensitive Ca 2+ channels and release of Ca 2+ from storage sites located at the inner surface of the cell membrane which is obviously inositol 1,4,5-trisphosphate (IP 3 )-sensitive. The myogenic reaction of an isolated vascular segment in response to such mechanical forces is a response that requires cellular signal transduction and intracellular pathways that are common to pharmacological agonists thereby leading to post-thaw dierent modi®cation of vascular responses to various contractile agonists. These ®ndings suggest, therefore, that postoperative administration of Ca 2+ channel blocking drugs could be an eective treatment to prevent the development of spasms in arterial grafts.
